Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02317640
Other study ID # DOD SC130243
Secondary ID
Status Recruiting
Phase Phase 1/Phase 2
First received December 6, 2014
Last updated August 18, 2017
Start date March 15, 2017
Est. completion date October 2022

Study information

Verified date August 2017
Source Kessler Foundation
Contact Gail F Forrest, PhD
Phone 973-324-3518
Email gforrest@kesslerfoundation.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this study is to understand what happens to muscle and bone in spinal cord injured males after four months of training using stand training, with body weight support (BWS), with testosterone replacement therapy (TRT), and electrical stimulation (ES). Specifically, researchers will investigate nerve, muscle, and bone changes in the lower limbs in response to stand training and ES when combined with TRT compared to i) standing alone with TRT; ii) stand training alone with placebo; iii) stand training alone and ES with placebo.


Description:

Primary Aim:

To assess the effects of our novel tri combination Activity-Dependent Rehabilitation model approach on muscle volume of the lower limbs.

Secondary Aims:

i) To better define the mechanisms that contribute to changes in muscle.

Preliminary data from animal studies have shown increased expression of Activin receptor IIB and increased nuclear localization of Smad2 and Smad3 after SCI and that these adverse changes are reversed by androgens. Additional studies will examine mRNA levels for myostatin, its receptor and its inhibitors (e.g., follistatins) and determine nuclear levels of Smad2 and Smad3. We will also measure resting energy expenditure to confirm that changes in muscles mass correspond to anticipated metabolic effects.

ii) To evaluate the changes in bone and bone structure with Stand Training with TRT and ES.

Individuals with SCI not only lose motor and/or sensory function, they experience dramatic muscle and bone loss. Locomotor training, an activity-based intervention that engages the neuromuscular system below the level of lesion for standing and walking enhances EMG activity and has shown modest improvements in muscle without any attenuation in bone density [172-177]. Dynamic stand training, an important component of locomotor training, provides sensory feedback related to standing and bilateral weight bearing, resulting in bilateral muscle activation via central pathways through the spinal cord [161,178-181]. Thus, the stand retraining component provides a physiologically relevant multi-muscle activation through central pathways, dynamic gravity opposed loading of the legs and additional task specific activation of the muscles [161,162,179]. Functional electrical stimulation is a method of exercise that has been employed in the SCI population and has demonstrated success in improving muscle, with less conclusive evidence for its effect on bone albeit there has been speculation that although slowing or preventing bone loss may be feasible after SCI, reversing such bone loss (i.e. restoring bone) is not possible, although the evidence is primarily from applying FES to single muscles [151,171]. TRT has been shown to offer a logical, efficacious, and cost-effective intervention to, in part, counteract these untoward body composition, metabolic, and functional sequelae of relative hypogonadism in those with chronic SCI [37]. In addition, testosterone alone has been shown to increase muscle mass, muscle strength, and bone in androgen-deficient men and older men with low testosterone levels [182,183]. The model of compressive loads generated during the combination of stand retraining and multi muscle ES will be multi-directional and will increase muscle strength and the forces applied to the hip, femur and tibia bones. We anticipate that the model of standing plus TRT will increase muscle mass and strength more than standing alone. The combination of multi muscle TRT+ES while stand training will further increase muscle strength compared to either arm alone, resulting in an increased synergistic response of benefit which will surpass the threshold needed to significantly increase bone restoration [102,184,185].This novel tri-combination synergistic approach of TRT, ES, and Stand Training is being hypothesized to increase muscle mass and strength to a greater extent than that of each alone or than that of only two of these interventions. Measurements of muscle torques will be obtained to demonstrate a quantifiable relationship between muscle strength and bone mass.


Recruitment information / eligibility

Status Recruiting
Enrollment 56
Est. completion date October 2022
Est. primary completion date October 2022
Accepts healthy volunteers No
Gender Male
Age group 18 Years to 58 Years
Eligibility Inclusion Criteria:

1. Must be a male between 18 and 58 years old;

2. Must have a spinal cord injury at a neurological level of injury between the C6-T10 level and an impairment grade A, B, or C, according to the American Spinal Injury Association (ASIA) Impairment Scale. If a person with quadriplegia their motor level will be used instead of neurological level. As a quadraplegic the motor level must be between C6-T10;

3. Must be able to tolerate electrical stimulation and must show visible muscle contraction to an electrical stimulus;

4. Must be wheelchair reliant for more than 75% of the time;

5. Must have low testosterone levels (300-325 ng/dL) as determined by a blood test done at the baseline study visit.

Exclusion Criteria:

1. Taking spasticity medication (i.e., baclofen). It may be possible that participant can be weaned off of the spasticity medication prior to starting entry into the study. This would be under the guidance of the study physician.

2. Less than 6 months or greater than 10 years post injury;

3. A score >3 on the Modified Ashworth Scale as determined by study staff;

4. Bone density measurement for the knee is at or below .5755 gm/cm2 as recorded by study staff;

5. Weigh more than 225 lbs;

6. Taller than 6 feet 3 inches;

7. Presence of a cardiovascular disease;

8. Presence of pulmonary disease;

9. Presence of recent lower limb fractures;

10. Presence of severe contractures;

11. Presence of lower extremity deep vein thrombosis (within the last three months) or other major medical illness;

12. Taking medications known to influence bone metabolism as determined by study staff review of medications;

13. A major gastrointestinal problem such as swallowing or gastrointestinal reflux disease;

14. Heart rate or rhythm problems;

15. A pacemaker;

16. Had spinal fusion, must have approval from the referring physician to receive ES - assisted standing prior to acceptance into the study;

17. As determined by study staff and review of medications, taking medication known to affect my level of testosterone;

18. A PSA greater than or equal to 4.0 ng/ml as determined by blood tests during screening visit;

19. An elevated PSA or asymmetry or hardening of prostate as determined by blood tests and digital rectal examination at screening visit.

20. Any known heart or blood vessel problems (cardiovascular disease)

21. An acute illness of any cause;

22. History of anabolic steroid use as determined by study staff review of participant's medical records;

23. Have a hematocrit greater than or equal to 55 as measured by the study team.

24. Have an abnormal liver function test from the hepatic panel (greater than 2.5 times the normal value) as measured by the study team;

25. Have an abnormal digital rectal exam (DRE) at baseline suggestive of malignancy;

26. Currently abuse alcohol or drugs;

27. Have a significant psychological disorder;

28. Have a history of or a current malignancy;

29. Wish to contribute to the conception of a child.

If any of the following occurs in the experimental group following initiation of testosterone replacement therapy participation will be terminated.

1. Hematocrit greater than or equal to 55;

2. Abnormal liver function test from the hepatic panel (greater than 2.5 times the normal value);

3. Worsening of any sleep disorder, as determined by the Investigators;

4. A PSA greater than or equal to 4.0 ng/ml;

5. Worsening of mood disorders; i.e. anger and depression as determined by the investigators;

6. Planning to contribute to the conception of a child during the study period.

7. Have participated in an electrical stimulation or TRT study in the previous 3 months.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Testosterone Gel applied by a pump
After being diagnosed with low testosterone levels the participant will be given a 30-day supply of the Testosterone/placebo gel (40.5 mg/day). The gel is to be applied every morning on clean and dry area of skin of the upper arms and shoulders.
Other:
Stand Training
Stand training with BWST with manual assistance. Participant is placed on treadmill in an upright position and suspended in a harness by an overhead cable. A trainer will aid the participant in pelvis and trunk stabilization, by applying anterior forces at the pelvis and/or posterior forces at the shoulders and ensure that the trunk and pelvis are not flexed or hyper-extended.
Device:
Electrical Stimulation
Electrical Stimulation (ES) will be applied via bifurcated leads and self-adhesive reusable surface electrodes. The electrodes will be applied over the motor points of both legs. Two electrodes will be used for contracting each muscle.

Locations

Country Name City State
United States Kessler Foundation West Orange New Jersey

Sponsors (2)

Lead Sponsor Collaborator
Kessler Foundation United States Department of Defense

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Muscle Volume (percent change in muscle volume for the bilateral thigh) Muscle volume will be measured in the thigh. The percent change in muscle volume for the bilateral thigh will be compared to before the intervention to after the intervention. 38 weeks
Secondary Change in Muscle (increase in muscle torque) To assess whether the tri-combination of stand training with TRT and ES will lead to increased muscle strength and contractile elements of muscle as shown by an increase in muscle torque. 38 weeks
Secondary Change in Bone (BMD of the proximal tibia and distal femur) To evaluate change in bone and bone structure with stand training with TRT and ES will include BMD of the proximal tibia and distal femur; these are the most common sites for fracture and may also respond faster to intervention. Other secondary outcome measures will be BMD at the hip, cortical and trabecular bone with 3-D volumetric measurements, and bone markers for formation and resorption. 38 Weeks
See also
  Status Clinical Trial Phase
Recruiting NCT02574572 - Autologous Mesenchymal Stem Cells Transplantation in Cervical Chronic and Complete Spinal Cord Injury Phase 1
Recruiting NCT05941819 - ARC Therapy to Restore Hemodynamic Stability and Trunk Control in People With Spinal Cord Injury N/A
Completed NCT05265377 - Safety and Usability of the STELO Exoskeleton in People With Acquired Brain Injury and Spinal Cord Injury N/A
Recruiting NCT02331979 - Improving Bladder Function in SCI by Neuromodulation N/A
Completed NCT02777281 - Safe and Effective Shoulder Exercise Training in Manual Wheelchair Users With SCI N/A
Recruiting NCT02978638 - Electrical Stimulation for Continence After Spinal Cord Injury N/A
Completed NCT02161913 - Comparison of Two Psycho-educational Family Group Interventions for Persons With SCI and Their Caregivers N/A
Completed NCT02262234 - Education Interventions for Self-Management of Pain Post-SCI: A Pilot Study Phase 1/Phase 2
Withdrawn NCT02237547 - Safety and Feasibility Study of Cell Therapy in Treatment of Spinal Cord Injury Phase 1/Phase 2
Completed NCT01884662 - Virtual Walking for Neuropathic Pain in Spinal Cord Injury N/A
Terminated NCT02080039 - Electrical Stimulation of Denervated Muscles After Spinal Cord Injury N/A
Completed NCT01642901 - Zoledronic Acid in Acute Spinal Cord Injury Phase 3
Terminated NCT01433159 - Comparison of HP011-101 to Standard Care for Stage I-II Pressure Ulcers in Subjects With Spinal Cord Injury Phase 2
Completed NCT01471613 - Lithium, Cord Blood Cells and the Combination in the Treatment of Acute & Sub-acute Spinal Cord Injury Phase 1/Phase 2
Completed NCT02149511 - Longitudinal Morphometric Changes Following SCI
Completed NCT01467817 - Obesity/Overweight in Persons With Early and Chronic Spinal Cord Injury (SCI) N/A
Completed NCT01086930 - Early Intensive Hand Rehabilitation After Spinal Cord Injury Phase 3
Completed NCT00663663 - Telephone Intervention for Pain Study (TIPS) N/A
Completed NCT01025609 - Dietary Patterns and Cardiovascular (CVD) Risk in Spinal Cord Injury (SCI) Factors In Individuals With Chronic Spinal Cord Injury
Terminated NCT01005615 - Patterned Functional Electrical Stimulation (FES) Ergometry of Arm and Shoulder in Individuals With Spinal Cord Injury Phase 1/Phase 2